Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial.

dc.contributor.authorGonzález-Huix Lladó, Ferrancat
dc.contributor.authorLeón, R. decat
dc.contributor.authorFernández Bañares, Fernandocat
dc.contributor.authorEsteve i Comas, Mariacat
dc.contributor.authorCabré i Gelada, Eduardcat
dc.contributor.authorAcero i Fernández, Doroteocat
dc.contributor.authorAbad, Águedacat
dc.contributor.authorFiga, M.cat
dc.contributor.authorGuilera Sardà, Magdacat
dc.contributor.authorPlanas Vilà, Ramoncat
dc.contributor.authorGassull, Miquel Àngelcat
dc.date.accessioned2011-07-07T12:31:02Z
dc.date.available2011-07-07T12:31:02Z
dc.date.issued1993
dc.description.abstractThirty two patients with active Crohn's disease were included in a controlled randomised trial to determine the efficacy and safety of polymeric enteral nutrition compared with steroids, to achieve and maintain clinical remission. The polymeric diet was administered through a fine bore nasogastric tube by continuous, pump assisted infusion (2800 (SEM 120) kcal/day). The steroid group received 1 mg/kg/day of prednisone. Both treatments were effective in inducing clinical remission: 15 of the 17 patients given steroids and 12 of the 15 patients assigned to the polymeric diet went into clinical remission (defined by a Van Hees index < 120) within four weeks of treatment. The percentage reduction of the Van Hees index was 34.8 (4.9)% for steroids and 32.3 (5)% for enteral nutrition (mean difference 2.5%; 95% CI--11.8% to +16.8%). Mean time elapsed to achieve remission was similar in both groups (2.0 (1) v 2.4 (1.2) weeks). Tolerance of the enteral diet was excellent. Four patients in the steroid group had mild complications attributable to this treatment. Ten patients (66.6%) in the steroid group and five (41.6%) in the enteral nutrition group relapsed within a year of discharge, but no differences were found in the cumulative probability of relapse during the follow up period. These results suggest that polymeric enteral nutrition is as safe and effective as steroids in inducing short term remission in active Crohn's disease.
dc.format.extent5 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec160892
dc.identifier.issn0017-5749
dc.identifier.pmid8314510
dc.identifier.urihttps://hdl.handle.net/2445/18678
dc.language.isoengeng
dc.publisherBMJ Groupeng
dc.relation.isformatofReproducció digital del document publicat a: http://dx.doi.org/10.1136/gut.34.6.778cat
dc.relation.ispartofGut, 1993, vol. 34, núm. 6, p. 778-782
dc.relation.urihttp://dx.doi.org/10.1136/gut.34.6.778
dc.rights(c) BMJ Publishing Group Ltd and British Society of Gastroenterology, 1993
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationAlimentació enteralcat
dc.subject.classificationMalaltia de Crohncat
dc.subject.classificationAssaigs clínicscat
dc.subject.classificationEsteroidescat
dc.subject.otherEnteral feedingeng
dc.subject.otherCrohn's diseaseeng
dc.subject.otherClinical trialseng
dc.subject.otherSteroidseng
dc.titlePolymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial.eng
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
160892.pdf
Mida:
1.05 MB
Format:
Adobe Portable Document Format